Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981282 | 0.84 | HTR6 (0.64) | HTR6KMT2A | |
| SCHEMBL3907878 | 0.83 | KMT2A (0.48) | HTR6MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL3920245 | 0.83 | HTR6 (0.44) | HTR6MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL3916664 | 0.81 | HDAC1 (0.48) | HTR6MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL13912830 | 0.79 | KMT2A (0.46) | HTR6MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL3907708 | 0.79 | KMT2A (0.46) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL3982350 | 0.79 | HTR6 (1.00) | HTR6 | |
| SCHEMBL3920558 | 0.78 | HTR6 (1.00) | HTR6 | |
| Hydrochloric Acid SCHEMBL4087854 | 0.78 | HTR6 (0.98) | HTR6 | |
| SCHEMBL4078875 | 0.78 | HTR6 (0.82) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2024348-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | Wyeth (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885MEN1 3628/4885KMT2A 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.